{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:28:03Z","timestamp":1788996483138,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.iac.2020.07.001","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:20:47Z","timestamp":1599931247000},"page":"649-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders"],"prefix":"10.1016","volume":"40","author":[{"given":"Bianca","family":"Olivieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Caminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lunardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.iac.2007.07.004","article-title":"Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders","volume":"27","author":"Ackerman","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"10.1016\/j.iac.2020.07.001_bib2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1084\/jem.172.5.1425","article-title":"Eosinophilia in transgenic mice expressing interleukin 5","volume":"172","author":"Dent","year":"1990","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1084\/jem.173.2.429","article-title":"Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production","volume":"173","author":"Tominaga","year":"1991","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1074-7613(00)80294-0","article-title":"IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T\u00a0cell responses","volume":"4","author":"Kopf","year":"1996","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.183.1.195","article-title":"Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model","volume":"183","author":"Foster","year":"1996","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.iac.2020.07.001_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2020.07.001_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212587","article-title":"Targeting eosinophils: severe asthma and beyond","volume":"8","author":"Caminati","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.iac.2020.07.001_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: From the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"24","key":"10.1016\/j.iac.2020.07.001_bib10","first-page":"6072","article-title":"Eosinophils in mucosal immune responses","volume":"118","author":"Riaz","year":"2016","journal-title":"Mucosal Immunol"},{"issue":"4","key":"10.1016\/j.iac.2020.07.001_bib11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.V94.4.1429","article-title":"C\/EBP\u03b2 and GATA-1 synergistically regulate activity of the eosinophil granule major basic protein promoter: Implication for C\/EBP\u03b2 activity in eosinophil gene expression","volume":"94","author":"Yamaguchi","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2020.07.001_bib12","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V73.6.1504.1504","article-title":"Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF","volume":"73","author":"Clutterbuck","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4168\/aair.2012.4.2.68","article-title":"Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma","volume":"4","author":"Uhm","year":"2012","journal-title":"Allergy Asthma Immunol Res"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaci.2010.04.011","article-title":"Practical approach to the patient with hypereosinophilia","volume":"126","author":"Roufosse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2020.07.001_bib15","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood.V78.10.2702.2702","article-title":"Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1","volume":"78","author":"Wong","year":"1991","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iac.2020.07.001_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Flood-Page","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.177.3.839","article-title":"Adhesion to fibronectin prolongs eosinophil survival","volume":"177","author":"Anwar","year":"1993","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib18","article-title":"Eosinophil Apoptosis and Clearance in Asthma","volume":"6","author":"Walsh","year":"2013","journal-title":"J\u00a0Cell Death"},{"issue":"5","key":"10.1016\/j.iac.2020.07.001_bib19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaci.2016.09.011","article-title":"Innate lymphoid cells in allergic and nonallergic inflammation","volume":"138","author":"Morita","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1189\/jlb.0404228","article-title":"Eosinophils function as antigen-presenting cells","volume":"76","author":"Shi","year":"2004","journal-title":"J\u00a0Leukoc Biol"},{"issue":"8","key":"10.1016\/j.iac.2020.07.001_bib21","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.4049\/jimmunol.139.8.2661","article-title":"Purification and partial sequence analysis of murine B cell growth factor II (interleukin 5)","volume":"139","author":"McKenzie","year":"1987","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/meth.1996.0392","article-title":"Interleukin-5 and Human B Lymphocytes","volume":"11","author":"Baumann","year":"1997","journal-title":"Methods"},{"issue":"19","key":"10.1016\/j.iac.2020.07.001_bib23","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1073\/pnas.84.19.6629","article-title":"Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5)","volume":"84","author":"Campbell","year":"1987","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"7","key":"10.1016\/j.iac.2020.07.001_bib24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1182\/blood.V77.7.1462.1462","article-title":"Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors","volume":"77","author":"Denburg","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.iac.2020.07.001_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40413-018-0192-5","article-title":"Type 2 immunity in asthma","volume":"11","author":"Caminati","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"6","key":"10.1016\/j.iac.2020.07.001_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0092-8674(91)90040-6","article-title":"A\u00a0human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF","volume":"66","author":"Tavernier","year":"1991","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1359-6101(00)00019-8","article-title":"Specificity in cytokine signal transduction: lessons learned from the IL-3\/IL-5\/GM-CSF receptor family","volume":"12","author":"Geijsen","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"10.1016\/j.iac.2020.07.001_bib28","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood.V95.8.2491","article-title":"Structure of the activation domain of the GM-CSF\/IL-3\/IL-5 receptor common \u03b2-chain bound to an antagonist","volume":"95","author":"Rossjohn","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12016-014-8444-9","article-title":"Biological modulators in eosinophilic diseases","volume":"50","author":"Sriaroon","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10","key":"10.1016\/j.iac.2020.07.001_bib30","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood.V78.10.2542.2542","article-title":"Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils","volume":"78","author":"Yamaguchi","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-020-0881-2","article-title":"Eosinophilic vasculitis","volume":"22","author":"Vega Villanueva","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.iac.2020.07.001_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","article-title":"Eosinophils in vasculitis: characteristics and roles in pathogenesis","volume":"10","author":"Khoury","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.iac.2020.07.001_bib34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.iac.2020.07.001_bib35","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-factor score revisited","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.iac.2020.07.001_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11926-019-0835-8","article-title":"Treatment strategies in ANCA-associated vasculitis","volume":"21","author":"Emejuaiwe","year":"2019","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","article-title":"Sustained response to mepolizumab in refractory Churg-Strauss syndrome","volume":"125","author":"Kahn","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.07.001_bib39","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2020.07.001_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting Interleukin-5 in Refractory and Relapsing Churg\u2013Strauss Syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"issue":"1 Suppl 70","key":"10.1016\/j.iac.2020.07.001_bib41","first-page":"S62","article-title":"Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg-Strauss syndrome","volume":"30","author":"Herrmann","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"20","key":"10.1016\/j.iac.2020.07.001_bib42","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2020.07.001_bib43","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40413-018-0217-0","article-title":"Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases","volume":"11","author":"Celebi Sozener","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"9","key":"10.1016\/j.iac.2020.07.001_bib45","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s10067-017-3780-9","article-title":"Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"36","author":"Aguirre-Valencia","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2020.07.001_bib47","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.iac.2020.07.001_bib48","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jpeds.2009.01.058","article-title":"Treatment of a Case of Pediatric Hypereosinophilic Syndrome with Anti-Interleukin-5","volume":"155","author":"Mehr","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.iac.2020.07.001_bib50","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201907-1376IM","article-title":"The effect of mepolizumab on the lungs in a boy with hypereosinophilic syndrome","author":"Armoni Domany","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti\u2013interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes\u2606","volume":"113","author":"Garrett","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2020.07.001_bib52","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2020.07.001_bib53","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2020.07.001_bib55","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti\u2013interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2020.07.001_bib56","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/ddg.13926_g","article-title":"Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab","volume":"17","author":"Buttgereit","year":"2019","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.iac.2020.07.001_bib57","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.anai.2018.02.017","article-title":"Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab","volume":"120","author":"Kuruvilla","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"14","key":"10.1016\/j.iac.2020.07.001_bib58","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2020.07.001_bib59","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated International consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.iac.2020.07.001_bib60","article-title":"Eosinophilic esophagitis: the potential role of biologics in its treatment","author":"Choudhury","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.iac.2020.07.001_bib61","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"01","key":"10.1016\/j.iac.2020.07.001_bib62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.iac.2020.07.001_bib63","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa\u2019ad","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib64","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib65","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaci.2007.06.015","article-title":"Anti-IgE treatment of eosinophil-associated gastrointestinal disorders","volume":"120","author":"Foroughi","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2020.07.001_bib66","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00431-011-1540-4","article-title":"Omalizumab in the treatment of eosinophilic esophagitis and food allergy","volume":"170","author":"Rocha","year":"2011","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib67","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","article-title":"Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE","volume":"147","author":"Clayton","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib68","doi-asserted-by":"crossref","first-page":"e0113483","DOI":"10.1371\/journal.pone.0113483","article-title":"A\u00a0pilot study of omalizumab in eosinophilic esophagitis","volume":"10","author":"Loizou","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.anai.2019.11.018","article-title":"Future therapies for eosinophilic gastrointestinal disorders","volume":"124","author":"Pesek","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of Dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib71","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti\u2013IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib72","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.iac.2020.07.001_bib73","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/17476348.2016.1249853","article-title":"Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis","volume":"10","author":"Agarwal","year":"2016","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"10.1016\/j.iac.2020.07.001_bib74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2500\/aap.2019.40.4262","article-title":"Allergic bronchopulmonary aspergillosis","volume":"40","author":"Patel","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib75","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody","volume":"62","author":"van der Ent","year":"2007","journal-title":"Thorax"},{"issue":"507","key":"10.1016\/j.iac.2020.07.001_bib76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.iac.2020.07.001_bib77","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblond","year":"2011","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2020.07.001_bib79","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ppul.22937","article-title":"Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence","volume":"49","author":"Tanou","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.iac.2020.07.001_bib80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib81","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12890-018-0617-5","article-title":"A\u00a0case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"18","author":"Terashima","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.iac.2020.07.001_bib82","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.alit.2018.03.004","article-title":"Severe asthma concomitant with allergic bronchopulmonary aspergillosis successfully treated with mepolizumab","volume":"67","author":"Oda","year":"2018","journal-title":"Allergol Int"},{"issue":"3","key":"10.1016\/j.iac.2020.07.001_bib83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.alit.2018.12.008","article-title":"Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab","volume":"68","author":"Soeda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.iac.2020.07.001_bib84","first-page":"59","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: Case report and review of the literature","volume":"26","author":"Hirota","year":"2019","journal-title":"Respir Med Case Rep"},{"issue":"4","key":"10.1016\/j.iac.2020.07.001_bib85","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","article-title":"Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis","volume":"5","author":"Altman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2020.07.001_bib86","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jaip.2018.11.024","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with benralizumab","volume":"7","author":"Soeda","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2020.07.001_bib87","first-page":"3","article-title":"Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment","author":"Tomomatsu","year":"2020","journal-title":"Allergol Int"},{"issue":"4","key":"10.1016\/j.iac.2020.07.001_bib88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.alit.2019.05.006","article-title":"Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management","volume":"68","author":"Suzuki","year":"2019","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.iac.2020.07.001_bib89","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.jaip.2018.06.017","article-title":"A\u00a0case of chronic eosinophilic pneumonia successfully treated with mepolizumab","volume":"6","author":"To","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2020.07.001_bib90","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/02770903.2018.1534966","article-title":"Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia","volume":"56","author":"Lin","year":"2019","journal-title":"J\u00a0Asthma"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib91","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"issue":"9","key":"10.1016\/j.iac.2020.07.001_bib92","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2169\/internalmedicine.3606-19","article-title":"Promising effects of benralizumab on chronic eosinophilic pneumonia","volume":"59","author":"Isomoto","year":"2020","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib93","doi-asserted-by":"crossref","first-page":"154","DOI":"10.18176\/jiaci.0468","article-title":"Long-term treatment with anti-interleukin 5 antibodies in a patient with chronic eosinophilic pneumonia","volume":"30","author":"Shimizu","year":"2020","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2020.07.001_bib94","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","article-title":"Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia","volume":"142","author":"Kaya","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.iac.2020.07.001_bib95","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1378\/chest.12-2035","article-title":"Can omalizumab be effective in chronic eosinophilic pneumonia?","volume":"143","author":"Domingo","year":"2013","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.iac.2020.07.001_bib96","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3346\/jkms.2012.27.10.1261","article-title":"Successful treatment of chronic eosinophilic pneumonia with Anti-IgE therapy","volume":"27","author":"Shin","year":"2012","journal-title":"J\u00a0Korean Med Sci"},{"issue":"7","key":"10.1016\/j.iac.2020.07.001_bib97","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.arbres.2017.11.009","article-title":"Response to omalizumab in a patient with chronic eosinophilic pneumonia and poor response to corticosteroids","volume":"54","author":"Lavi\u00f1a-Soriano","year":"2018","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.iac.2020.07.001_bib98","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/TCRM.S207402","article-title":"A\u00a0case of chronic eosinophilic pneumonia in a patient treated with dupilumab","volume":"15","author":"Menzella","year":"2019","journal-title":"Ther Clin Risk Manag"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985612030045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985612030045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:30Z","timestamp":1760179470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985612030045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S088985612030045X"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2020.07.001","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2020.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}